RxDoctor Payments Data

Ako Bradford, MD

Internal Medicine · Amarillo, TXNPI 1891738712

Payments from drug & device makers

$3,890in general payments, 2019–2025

Across 236 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$755
  • Amgen$479
  • GSK$356
  • Johnson & Johnson$344
  • AstraZeneca$325
  • Takeda Pharmaceuticals U.S.A., Inc.$223
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,84399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,890 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$262,538
Medicare patients
321
Services billed
7,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol103$104,772
OzempicSemaglutide48$65,722
RybelsusSemaglutide40$39,325
GlyxambiEmpagliflozin/Linagliptin25$37,844
EliquisApixaban35$37,428
Tresiba Flextouch U-200Insulin Degludec45$30,988
JardianceEmpagliflozin23$30,855
JanuviaSitagliptin Phosphate23$28,371
XareltoRivaroxaban17$24,994
Janumet XrSitagliptin Phos/Metformin Hcl15$18,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,583
Levothyroxine Sodium232$3,236
Clonidine18$2,938
Enoxaparin Sodium11$2,543
BystolicNebivolol Hcl11$2,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$755$105,04888 claims
AstraZenecaFarxiga$325$104,772103 claims
Boehringer IngelheimGlyxambi, Jardiance$129$68,69948 claims
MerckJanuvia, Janumet Xr$11$46,61338 claims
PfizerEliquis, Paxlovid$118$38,85747 claims
Johnson & JohnsonXarelto$344$24,99417 claims
GSKTrelegy Ellipta$356$15,58316 claims
Kowa Pharmaceuticals America, Inc.Bystolic$129$2,26011 claims
AbbVieSynthroid$137$63013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →